What cardiac complications occur in patients with CREST syndrome and what is the recommended evaluation and management?

Cardiac Complications in CREST Syndrome

Patients with CREST syndrome primarily develop pulmonary arterial hypertension (PAH) leading to right ventricular dysfunction, while left ventricular abnormalities are typically minor and exercise-induced only.

Primary Cardiac Manifestation: Pulmonary Arterial Hypertension

The dominant cardiac complication in CREST syndrome is PAH, which occurs in 7-12% of systemic sclerosis patients and represents the second most common cause of PAH after idiopathic PAH 1. This is fundamentally different from diffuse scleroderma, where direct myocardial involvement predominates.

Right ventricular dysfunction in CREST syndrome results from pulmonary vascular disease rather than primary myocardial pathology 2. This manifests as:

• Isolated decrease in carbon monoxide diffusing capacity
• Progressive dyspnea and exercise intolerance
• Right heart failure symptoms
• Potentially fatal outcome if untreated 3

Left Ventricular Involvement: Minimal and Distinct

Left ventricular abnormalities in CREST syndrome are markedly different from diffuse scleroderma 2:

• Minor abnormalities seen only during exercise
• Thallium perfusion defects are smaller (64% prevalence but significantly smaller than diffuse scleroderma, p<0.01)
• No reperfusion defects in absence of coronary artery disease (unlike 38% in diffuse scleroderma)
• Cold exposure can induce transient segmental dysfunction 4

Arrhythmias and Conduction Abnormalities

Holter monitoring reveals significantly more abnormalities than resting ECG 5:

• Ventricular arrhythmias in 91% of patients (48/53)
• Multiform ventricular premature beats: 40%
• Ventricular tachycardia runs: 13%
• Conduction defects increase from 19% (resting ECG) to 30% (Holter)
• Transient ST-T changes increase from 4% to 34%

Critical point: Cardiac involvement shows no correlation with CREST versus diffuse scleroderma classification, making routine screening essential regardless of subtype 5.

Recommended Evaluation Algorithm

Initial Screening

1. Echocardiographic screening is recommended in all symptomatic CREST patients 1 to detect:

   • Elevated pulmonary artery pressures
   • Right ventricular dysfunction
   • Pericardial effusion (6% prevalence)
   • Asymmetric septal hypertrophy (19%)

2. 24-hour Holter monitoring should be included in routine workup 5 given the high prevalence of arrhythmias missed on standard ECG

3. Right heart catheterization is indicated when PAH is suspected, particularly if specific drug therapy is being considered 1

Asymptomatic Patients

Echocardiographic screening may be considered in asymptomatic patients with scleroderma spectrum disease (Class IIb recommendation) 1, though the evidence is weaker.

Management Recommendations

For PAH in CREST Syndrome

The same treatment algorithm as idiopathic PAH is recommended (Class I, Level A) 1:

1. First-line for WHO Functional Class III: Endothelin receptor antagonist bosentan (Class I, Level B) 1

2. Second-line considerations (Class IIa, Level C):

   • Other endothelin receptor antagonists
   • Phosphodiesterase type-5 inhibitors
   • Prostanoids

3. Calcium channel blockers are NOT recommended in CREST-associated PAH (Class III) 1, despite historical case reports showing benefit 6. This represents a critical pitfall to avoid.

For Cold-Induced Dysfunction

Nifedipine may blunt cold-induced segmental myocardial dysfunction 4, though this is distinct from PAH management and should not be confused with the contraindication for CCBs in established PAH.

Anticoagulation

Oral anticoagulation should be considered on an individual basis (Class IIa, Level C) 1, particularly in patients with:

• Pulmonary artery thrombosis
• Signs of heart failure
• Absence of significant hemoptysis risk

Supplemental Oxygen

Consider when it produces consistent increase in arterial oxygen saturation and reduces symptoms (Class IIa, Level C) 1.

Common Pitfalls

1. Relying solely on resting ECG: Misses 70% of conduction abnormalities and 90% of ST-T changes 5

2. Assuming benign cardiac course: PAH in CREST can be rapidly fatal 3, requiring aggressive screening and early intervention

3. Using calcium channel blockers for PAH: Despite older case reports, current guidelines explicitly contraindicate CCBs in Eisenmenger's and PAH 1

4. Overlooking right heart catheterization: Essential for confirming PAH diagnosis and guiding specific therapy 1

5. Missing the distinction from diffuse scleroderma: CREST has predominantly pulmonary vascular disease rather than primary myocardial involvement, fundamentally changing the management approach 2